AAM
NVAX icon

Aureus Asset Management’s Novavax NVAX Stock Holding History

Aureus Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,428
Closed -$494K – 176
2018
Q4 		$494K Buy
13,428
+239
+2% +$9.26K 0.08% 99
2018
Q3 		$496K Buy
+13,189
New +$371K 0.06% 109

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Aureus Asset Management's NVAX Position: Q1 2019 in Review

Aureus Asset Management sold out of Novavax (NVAX) in Q1 2019, closing a stake of 13,428 shares — an estimated $494K sold.

Aureus Asset Management first reported a position in NVAX in Q3 2018 and held it in 2 quarters. The position peaked at $496K in Q3 2018. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

  • Aureus Asset Management reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
  • Aureus Asset Management sold 13,428 Novavax shares in Q1 2019, an estimated $494K.
  • Aureus Asset Management first reported a position in Novavax in Q3 2018 and held it in 2 quarters.
  • Aureus Asset Management's Novavax position peaked at $496K in Q3 2018.
  • 140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Aureus Asset Management's 13F filing for Q1 2019, filed 13 May 2019.